3%) maintained clinical remission at week-26. Younger age, disease duration ≤3 years, absence of a history of bowel resection and absence of prior anti-TNF therapy were associated with clinical remission at week-4 upon u nivariate analyses (p = 0.03, 0.02, 0.001 and 0.004, respectively). Absence of a history of bowel resection

and prior anti-TNF therapy were predictive factors for clinical selleck inhibitor remission at week-4 upon multivariate logistic regression analyses (p = 0.03; odds ratio (OR), 9.00; 95% confidence interval (CI), 1.30–62.32; 0.04; 6.95; 1.07–45.00, respectively). Younger age and disease duration ≤3 years correlated with clinical remission at week-26 upon univariate analyses (p = 0.03 and 0.009, respectively). No patient contracted a serious infectious disease. Conclusion: Younger age, shorter duration of disease, being naïve to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA for induction and maintenance of clinical remission in CD patients. Key Word(s): 1. Crohn; 2. adalimumab Presenting Author: JONG KWAN JUNG Additional Authors: click here DONG SOO HAN, YOUNGOUK RO, A. REUM LEE, JI YEOUN KIM, CHANG SOO EUN, KYO SANG YOO Corresponding Author: JONG KWAN JUNG Affiliations: Hanyang University Guri Hospital, Hanyang University Guri Hospital, Hanyang University Guri Hospital, Hanyang University Guri Hospital, Hanyang University Guri Hospital, Hanyang University Guri

Hospital Objective: It has been well known that genetic mutations and the epidemiology of inflammatory bowel disease (IBD) differ between Asia and the

West. However, TNF superfamily member 15 (TNFSF15) gene has been identified as a common susceptibility gene in Asian and Western IBD patients, suggesting that TNFSF15 may play an important role in the pathogenesis of IBD. TNFSF15/TNF-like cytokine 1A (TL1A) is a proinflammatory cytokine and a member of the TNFαsuperfamily, mainly expressed on activated T cells. We investigated mucosal TL1A expression by immunohistochemistry (IHC) in Korean IBD patients. Methods: TL1A expression was investigated in resected ileal specimens from 8 Crohn’s disease (CD) patients and 8 non-IBD controls 上海皓元医药股份有限公司 by IHC using an affinity-purified mAb against TL1A. TL1A expression was also studied in endoscopically biopsied colonic specimens from 8 ulcerative colitis patients and 8 non-IBD controls. In addition, the mucosal expressions of CD3, CD4, and CD8, T cell markers, were examined in ileal and colonic specimens of IBD patients and non-IBD controls. Results: The expression of TL1A at the protein level was absent or minimal in ileal and colonic tissues from controls. On the contrary, intense expression of TL1A was identified in ileal and colonic specimens from IBD patients, especially in CD patients. Staining for TL1A was significantly increased in inflammed area of ileal tissues compared to non-inflammed area from CD patients.